Neuroprotection in glaucoma: Present and future

Chinese Medical Journal

Volumn 126, Issue 8, 2013, Pages 1567-1577

  Chen, Shi Da ^a   Wang, Lu ^a   Zhang, Xiu Lan ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Glaucoma; Neuroprotection; Retinal ganglion cells

Indexed keywords

APOPTOSIS SIGNAL REGULATING KINASE 1; BRAIN DERIVED NEUROTROPHIC FACTOR; BRIMONIDINE; CILIARY NEUROTROPHIC FACTOR; DIZOCILPINE; ENDOTHELIN 1; GINKGO BILOBA EXTRACT; LOMERIZINE; MELATONIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPROTECTIVE AGENT; NEUROTROPHIN; NILVADIPINE; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; THIOREDOXIN; TUMOR NECROSIS FACTOR ALPHA; UBIDECARENONE;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; CELL DEATH; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DAMAGE; EXCITOTOXICITY; FOLLOW UP; GENE MUTATION; GENE THERAPY; GLAUCOMA; GLIA CELL; HUMAN; INFLAMMATION; INTRAOCULAR PRESSURE; ISCHEMIA; NERVE FIBER DEGENERATION; NEUROPROTECTION; NONHUMAN; OPTIC NERVE DISEASE; OXIDATIVE STRESS; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PUBLICATION; RETINA GANGLION CELL; RETINA ISCHEMIA; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; SYNAPTIC EFFICACY; VISUAL SYSTEM FUNCTION;

APOPTOSIS; AXONAL TRANSPORT; BRAIN-DERIVED NEUROTROPHIC FACTOR; CILIARY NEUROTROPHIC FACTOR; GLAUCOMA; HUMANS; MITOCHONDRIA; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PROTEIN FOLDING; RECEPTORS, N-METHYL-D-ASPARTATE; RETINAL GANGLION CELLS;

EID: 84876353544     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20123565     Document Type: Review

References (139)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90: 262-267.
2. Quigley HA. Glaucoma. Lancet 2011; 377: 1367-1377.
3. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. The Ocular Hypertension Treatment Study: a randomized trial determines thattopical ocular hypotensive medication delays or prevents the onset of primaryopen-angle glaucoma. Arch Ophthalmol 2002; 120: 701-713; discussion 829-830.
4. Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Studycomparing initial treatment randomized to medications or surgery. Ophthalmology 2001; 108: 1943-1953.
5. Musch DC, Gillespie BW, Lichter PR, Niziol LM, Janz NK. Visual field progression in the Collaborative Initial Glaucoma Treatment Studythe impact of treatment and other baseline factors. Ophthalmology 2009; 116: 200-207.
6. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003; 121: 48-56.
7. Chang EE, Goldberg JL. Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement. Ophthalmology 2012; 119: 979-986.
8. Weinreb RN. Glaucoma neuroprotection: What is it? Why is it needed. Can J Ophthalmol 2007; 42: 396-398.
9. Osborne NN. Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta Ophthalmol 2009; 87: 450-454.
10. Teng KK, Hempstead BL. Neurotrophins and their receptors: signaling trios in complex biological systems. Cell Mol Life Sci 2004; 61: 35-48.
11. Miller FD, Kaplan DR. Neurotrophin signalling pathways regulating neuronal apoptosis. Cell Mol Life Sci 2001; 58: 1045-1053.
12. Lebrun-Julien F, Bertrand MJ, De Backer O, Stellwagen D, Morales CR, Di PA, et al. ProNGF induces TNF alpha-dependent death of retinal ganglion cells through ap75NTR non-cell-autonomous signaling pathway. Proc Natl Acad Sci U S A 2010; 107: 3817-3822.
13. Pasutto F, Matsumoto T, Mardin CY, Sticht H, Brandstatter JH, Michels-Rautenstrauss K, et al. Heterozygous NTF4 mutations impairing neurotrophin-4 signaling in patients with primary open-angle glaucoma. Am J Hum Genet 2009; 85: 447-456.
14. Lambiase A, Aloe L, Centofanti M, Parisi V, Mantelli F, Colafrancesco V, et al. Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma. Proc Natl Acad Sci U S A 2009; 106: 13469-13474.
15. Martin KR, Quigley HA, Zack DJ, Levkovitch-Verbin H, Kielczewski J, Valenta D, et al. Gene therapy with brain-derived neurotrophic factor as a protection: retinalganglion cells in a rat glaucoma model. Invest Ophthalmol Vis Sci 2003; 44: 4357-4365.
16. Chen H, Weber AJ. BDNF enhances retinal ganglion cell survival in cats with optic nerve damage. Invest Ophthalmol Vis Sci 2001; 42: 966-974.
17. Koeberle PD, Ball AK. Neurturin enhances the survival of axotomized retinal ganglion cells in vivo: combined effects with glial cell line-derived neurotrophic factor andbrain-derived neurotrophic factor. Neuroscience 2002; 110: 555-567.
18. Arancio O, Chao MV. Neurotrophins, synaptic plasticity and dementia. Curr Opin Neurobiol 2007; 17: 325-330.
19. Schmidt H, Rathjen FG. Signalling mechanisms regulating axonal branching in vivo. Bioessays 2010; 32: 977-985.
20. Weber AJ, Harman CD. BDNF preserves the dendritic morphology of alpha and beta ganglion cells in thecat retina after optic nerve injury. Invest Ophthalmol Vis Sci 2008; 49: 2456-2463.
21. Chun MH, Ju WK, Kim KY, Lee MY, Hofmann HD, Kirsch M, et al. Upregulation of ciliary neurotrophic factor in reactive Muller cells in the ratretina following optic nerve transection. Brain Res 2000; 868: 358-362.
22. Wu Q, Zhang M, Song BW, Lu B, Hu P. Expression of ciliary neurotrophic factor after induction of ocular hypertension in the retina of rats. Chin Med J 2007; 120: 1825-1829.
23. Pease ME, Zack DJ, Berlinicke C, Bloom K, Cone F, Wang Y, et al. Effect of CNTF on retinal ganglion cell survival in experimental glaucoma. Invest Ophthalmol Vis Sci 2009; 50: 2194-2200.
24. Ji JZ, Elyaman W, Yip HK, Lee VW, Yick LW, Hugon J, et al. CNTF promotes survival of retinal ganglion cells after induction of ocularhypertension in rats: the possible involvement of STAT3 pathway. Eur J Neurosci 2004; 19: 265-272.
25. Leaver SG, Cui Q, Plant GW, Arulpragasam A, Hisheh S, Verhaagen J, et al. AAV-mediated expression of CNTF promotes long-term survival and regeneration ofadult rat retinal ganglion cells. Gene Ther 2006; 13: 1328-1341.
26. McGill TJ, Prusky GT, Douglas RM, Yasumura D, Matthes MT, Nune G, et al. Intraocular CNTF reduces vision in normal rats in a dose-dependent manner. Invest Ophthalmol Vis Sci 2007; 48: 5756-5766.
27. Skaper SD. Peptide mimetics of neurotrophins and their receptors. Curr Pharm Des 2011; 17: 2704-2718.
28. Gozes I. Neuroprotective peptide drug delivery and development: potential new therapeutics. Trends Neurosci 2001; 24: 700-705.
29. Lagreze WA, Pielen A, Steingart R, Schlunck G, Hofmann HD, Gozes I, et al. The peptides ADNF-9 and NAP increase survival and neurite outgrowth of ratretinal ganglion cells in vitro. Invest Ophthalmol Vis Sci 2005; 46: 933-938.
30. Cheng L, Sapieha P, Kittlerova P, Hauswirth WW, Di PA. TrkB gene transfer protects retinal ganglion cells from axotomy-induced death in vivo. J Neurosci 2002; 22: 3977-3986.
31. Logan A, Ahmed Z, Baird A, Gonzalez AM, Berry M. Neurotrophic factor synergy is required for neuronal survival and disinhibitedaxon regeneration after CNS injury. Brain 2006; 129: 490-502.
32. Almasieh M, Wilson AM, Morquette B, Cueva VJL, Di PA. The molecular basis of retinal ganglion cell death in glaucoma. Prog Retin Eye Res 2012; 31: 152-181.
33. Seki M, Lipton SA. Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma. Prog Brain Res 2008; 173: 495-510.
34. Schuettauf F, Stein T, Choragiewicz TJ, Rejdak R, Bolz S, Zurakowski D, et al. Caspase inhibitors protect against NMDA-mediated retinal ganglion cell death. Clin Experiment Ophthalmol 2011; 39: 545-554.
35. Dong CJ, Guo Y, Agey P, Wheeler L, Hare WA. Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity. Invest Ophthalmol Vis Sci 2008; 49: 4515-4522.
36. Wamsley S, Gabelt BT, Dahl DB, Case GL, Sherwood RW, May CA, et al. Vitreous glutamate concentration and axon loss in monkeys with experimentalglaucoma. Arch Ophthalmol 2005; 123: 64-70.
37. Honkanen RA, Baruah S, Zimmerman MB, Khanna CL, Weaver YK, Narkiewicz J, et al. Vitreous amino acid concentrations in patients with glaucoma undergoing vitrectomy. Arch Ophthalmol 2003; 121: 183-188.
38. Hartwick AT, Hamilton CM, Baldridge WH. Glutamatergic calcium dynamics and deregulation of rat retinal ganglion cells. J Physiol 2008; 586: 3425-3446.
39. Furukawa Y, Okada M, Akaike N, Hayashi T, Nabekura J. Reduction of voltage-dependent magnesium block of N-methyl-D-aspartatereceptor-mediated current by in vivo axonal injury. Neuroscience 2000; 96: 385-392.
40. Hare WA, WoldeMussie E, Lai RK, Ton H, Ruiz G, Chun T, et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: functional measures. Invest Ophthalmol Vis Sci 2004; 45: 2625-2639.
41. Yucel YH, Gupta N, Zhang Q, Mizisin AP, Kalichman MW, Weinreb RN. Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma. Arch Ophthalmol 2006; 124: 217-225.
42. Osborne NN. Recent clinical findings with memantine should not mean that the idea ofneuroprotection in glaucoma is abandoned. Acta Ophthalmol 2009; 87: 450-454.
43. Russo R, Cavaliere F, Berliocchi L, Nucci C, Gliozzi M, Mazzei C, et al. Modulation of pro-survival and death-associated pathways under retinalischemia/reperfusion: effects of NMDA receptor blockade. J Neurochem 2008; 107: 1347-1357.
44. Guo L, Salt TE, Maass A, Luong V, Moss SE, Fitzke FW, et al. Assessment of neuroprotective effects of glutamate modulation on glaucoma-relatedretinal ganglion cell apoptosis in vivo. Invest Ophthalmol Vis Sci 2006; 47: 626-633.
45. Cross JV, Templeton DJ. Thiol oxidation of cell signaling proteins: Controlling an apoptotic equilibrium. J Cell Biochem 2004; 93: 104-111.
46. Andersen JK. Oxidative stress in neurodegeneration: cause or consequence. Nat Med 2004; 10: S18-S25.
47. Kanamori A, Catrinescu MM, Kanamori N, Mears KA, Beaubien R, Levin LA. Superoxide is an associated signal for apoptosis in axonal injury. Brain 2010; 133: 2612-2625.
48. Moreno MC, Campanelli J, Sande P, Sanez DA, Keller SMI, Rosenstein RE. Retinal oxidative stress induced by high intraocular pressure. Free Radic Biol Med 2004; 37: 803-812.
49. Yuki K, Ozawa Y, Yoshida T, Kurihara T, Hirasawa M, Ozeki N, et al. Retinal ganglion cell loss in superoxide dismutase 1 deficiency. Invest Ophthalmol Vis Sci 2011; 52: 4143-4150.
50. Swanson KI, Schlieve CR, Lieven CJ, Levin LA. Neuroprotective effect of sulfhydryl reduction in a rat optic nerve crush model. Invest Ophthalmol Vis Sci 2005; 46: 3737-3741.
51. Tezel G, Yang X, Cai J. Proteomic identification of oxidatively modified retinal proteins in a chronicpressure-induced rat model of glaucoma. Invest Ophthalmol Vis Sci 2005; 46: 3177-3187.
52. Caprioli J, Munemasa Y, Kwong JM, Piri N. Overexpression of thioredoxins 1 and 2 increases retinal ganglion cell survival after pharmacologically induced oxidative stress, optic nerve transection, and inexperimental glaucoma. Trans Am Ophthalmol Soc 2009; 107: 161-165.
53. Siu AW, Ortiz GG, Benitez-King G, To CH, Reiter RJ. Effects of melatonin on the nitric oxide treated retina. Br J Ophthalmol 2004; 88: 1078-1081.
54. Yancheva S, Ihl R, Nikolova G, Panayotov P, Schlaefke S, Hoerr R. Ginkgo biloba extract EGb 761(R), donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: a randomised, double-blind, exploratory trial. Aging Ment Health 2009; 13: 183-190.
55. Quaranta L, Bettelli S, Uva MG, Semeraro F, Turano R, Gandolfo E. Effect of Ginkgo biloba extract on preexisting visual field damage in normal tension glaucoma. Ophthalmology 2003; 110: 359-362; discussion 362-364.
56. Hirooka K, Tokuda M, Miyamoto O, Itano T, Baba T, Shiraga F. The Ginkgo biloba extract (EGb 761) provides a neuroprotective effect on retinal ganglion cells in a rat model of chronic glaucoma. Curr Eye Res 2004; 28: 153-157.
57. Thiagarajan G, Chandani S, Harinarayana RS, Samuni AM, Chandrasekaran K, Balasubramanian D. Molecular and cellular assessment of ginkgo biloba extract as a possible ophthalmic drug. Exp Eye Res 2002; 75: 421-430.
58. Cheung ZH, Yip HK, Wu W, So KF. Axotomy induces cytochrome C release in retinal ganglion cells. Neuroreport 2003; 14: 279-282.
59. Wang L, Dong J, Cull G, Fortune B, Cioffi GA. Varicosities of intraretinal ganglion cell axons in human and nonhuman primates. Invest Ophthalmol Vis Sci 2003; 44: 2-9.
60. Ames A 3rd. CNS energy metabolism as related to function. Brain Res Brain Res Rev 2000; 34: 42-68.
61. Baltan S, Inman DM, Danilov CA, Morrison RS, Calkins DJ, Horner PJ. Metabolic vulnerability disposes retinal ganglion cell axons to dysfunction in a model of glaucomatous degeneration. J Neurosci 2010; 30: 5644-5652.
62. Hu H, Lu W, Zhang M, Zhang X, Argall AJ, Patel S, et al. Stimulation of the P2X7 receptor kills rat retinal ganglion cells in vivo. Exp Eye Res 2010; 91: 425-432.
63. Schober MS, Chidlow G, Wood JP, Casson RJ. Bioenergetic-based neuroprotection and glaucoma. Clin Experiment Ophthalmol 2008; 36: 377-385.
64. Lee S, Van Bergen NJ, Kong GY, Chrysostomou V, Waugh HS, O'Neill EC, et al. Mitochondrial dysfunction in glaucoma and emerging bioenergetic therapies. Exp Eye Res 2011; 93: 204-212.
65. Jones AW, Yao Z, Vicencio JM, Karkucinska-Wieckowska A, Szabadkai G. PGC-1 family coactivators and cell fate: roles in cancer, neurodegeneration, cardiovascular disease and retrograde mitochondria-nucleus signalling. Mitochondrion 2012; 12: 86-99.
66. Nakajima Y, Inokuchi Y, Nishi M, Shimazawa M, Otsubo K, Hara H. Coenzyme Q10 protects retinal cells against oxidative stress in vitro and in vivo. Brain Res 2008; 1226: 226-233.
67. Nucci C, Tartaglione R, Cerulli A, Mancino R, Spano A, Cavaliere F, et al. Retinal damage caused by high intraocular pressure-induced transient ischemia is prevented by coenzyme Q10 in rat. Int Rev Neurobiol 2007; 82: 397-406.
68. Tezel G. Immune regulation toward immunomodulation for neuroprotection in glaucoma. Curr Opin Pharmacol 2013;13: 23-31.
69. Tezel G. The role of glia, mitochondria, and the immune system in glaucoma. Invest Ophthalmol Vis Sci 2009; 50: 1001-1012.
70. Lebrun-Julien F, Duplan L, Pernet V, Osswald I, Sapieha P, Bourgeois P, et al. Excitotoxic death of retinal neurons in vivo occurs via a non-cell-autonomousmechanism. J Neurosci 2009; 29: 5536-5545.
71. Nakazawa T, Nakazawa C, Matsubara A, Noda K, Hisatomi T, She H, et al. Tumor necrosis factor-alpha mediates oligodendrocyte death and delayed retinalganglion cell loss in a mouse model of glaucoma. J Neurosci 2006; 26: 12633-12641.
72. Tezel G, Li LY, Patil RV, Wax MB. TNF-alpha and TNF-alpha receptor-1 in the retina of normal and glaucomatous eyes. Invest Ophthalmol Vis Sci 2001; 42: 1787-1794.
73. Balaiya S, Edwards J, Tillis T, Khetpal V, Chalam KV. Tumor necrosis factor-alpha (TNF-alpha) levels in aqueous humor of primary openangle glaucoma. Clin Ophthalmol 2011; 5: 553-556.
74. Bozkurt B, Mesci L, Irkec M, Ozdag BB, Sanal O, Arslan U, et al. Association of tumour necrosis factor-alpha-308 G/A polymorphism with primaryopen-angle glaucoma. Clin Experiment Ophthalmol 2012; 40: e156-e162.
75. Tezel G, Yang X. Caspase-independent component of retinal ganglion cell death, in vitro. Invest Ophthalmol Vis Sci 2004; 45: 4049-4059.
76. Zang Y, Hong J, Robinson R, Li S, Rivera VM, Zhang JZ. Immune regulatory properties and interactions of copolymer-I and beta-interferon 1a in multiple sclerosis. J Neuroimmunol 2003; 137: 144-153.
77. Kipnis J, Yoles E, Porat Z, Cohen A, Mor F, Sela M, et al. T cell immunity to copolymer 1 confers neuroprotection on the damaged opticnerve: possible therapy for optic neuropathies. Proc Natl Acad Sci U S A 2000; 97: 7446-7451.
78. Bakalash S, Kessler A, Mizrahi T, Nussenblatt R, Schwartz M. Antigenic specificity of immunoprotective therapeutic vaccination for glaucoma. Invest Ophthalmol Vis Sci 2003; 44: 3374-3381.
79. Schori H, Kipnis J, Yoles E, WoldeMussie E, Ruiz G, Wheeler LA, et al. Vaccination for protection of retinal ganglion cells against death from glutamatecytotoxicity and ocular hypertension: implications for glaucoma. Proc Natl Acad Sci U S A 2001; 98: 3398-3403.
80. Hattori K, Naguro I, Runchel C, Ichijo H. The roles of ASK family proteins in stress responses and diseases. Cell Commun Signal 2009; 7: 9.
81. Harada C, Namekata K, Guo X, Yoshida H, Mitamura Y, Matsumoto Y, et al. ASK1 deficiency attenuates neural cell death in GLAST-deficient mice, a model of normal tension glaucoma. Cell Death Differ 2010; 17: 1751-1759.
82. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001; 410: 37-40.
83. Quigley HA, Cone FE, Gelman SE, Yang Z, Son JL, Oglesby EN, et al. Lack of neuroprotection against experimental glaucoma in c-Jun N-terminal kinase 3 knockout mice. Exp Eye Res 2011; 92: 299-305.
84. Fernandes KA, Harder JM, Fornarola LB, Freeman RS, Clark AF, Pang IH, et al. JNK2 and JNK3 are major regulators of axonal injury-induced retinal ganglion cell death. Neurobiol Dis 2012; 46: 393-401.
85. Malik JM, Shevtsova Z, Bahr M, Kugler S. Long-term in vivo inhibition of CNS neurodegeneration by Bcl-XL gene transfer. Mol Ther 2005; 11: 373-381.
86. Planchamp V, Bermel C, Tonges L, Ostendorf T, Kugler S, Reed JC, et al. BAG1 promotes axonal outgrowth and regeneration in vivo via Raf-1 and reductionof ROCK activity. Brain 2008; 131: 2606-2619.
87. Libby RT, Li Y, Savinova OV, Barter J, Smith RS, Nickells RW, et al. Susceptibility to neurodegeneration in a glaucoma is modified by Bax gene dosage. PLoS Genet 2005; 1: 17-26.
88. Li Y, Schlamp CL, Poulsen KP, Nickells RW. Bax-dependent and independent pathways of retinal ganglion cell death induced by different damaging stimuli. Exp Eye Res 2000; 71: 209-213.
89. Lingor P, Koeberle P, Kugler S, Bahr M. Down-regulation of apoptosis mediators by RNAi inhibits axotomy-induced retinalganglion cell death in vivo. Brain 2005; 128: 550-558.
90. Straten G, Schmeer C, Kretz A, Gerhardt E, Kugler S, Schulz JB, et al. Potential synergistic protection of retinal ganglion cells from axotomy-inducedapoptosis by adenoviral administration of glial cell line-derived neurotrophicfactor and X-chromosome-linked inhibitor of apoptosis. Neurobiol Dis 2002; 11: 123-133.
91. Wostyn P, Audenaert K, De Deyn PP. Alzheimer's disease and glaucoma: is there a causal relationship. Br J Ophthalmol 2009; 93: 1557-1559.
92. Goldblum D, Kipfer-Kauer A, Sarra GM, Wolf S, Frueh BE. Distribution of amyloid precursor protein and amyloid-beta immunoreactivity in DBA/2J glaucomatous mouse retinas. Invest Ophthalmol Vis Sci 2007; 48: 5085-5090.
93. Guo L, Salt TE, Luong V, Wood N, Cheung W, Maass A, et al. Targeting amyloid-beta in glaucoma treatment. Proc Natl Acad Sci U S A 2007; 104: 13444-13449.
94. Yamamoto R, Yoneda S, Hara H. Neuroprotective effects of beta-secretase inhibitors against rat retinal ganglioncell death. Neurosci Lett 2004; 370: 61-64.
95. Soti C, Nagy E, Giricz Z, Vigh L, Csermely P, Ferdinandy P. Heat shock proteins as emerging therapeutic targets. Br J Pharmacol 2005; 146: 769-780.
96. Tezel G, Hernandez R, Wax MB. Immunostaining of heat shock proteins in the retina and optic nerve head of normal and glaucomatous eyes. Arch Ophthalmol 2000; 118: 511-518.
97. Ishii Y, Kwong JM, Caprioli J. Retinal ganglion cell protection with geranylgeranylacetone, a heat shock protein inducer, in a rat glaucoma model. Invest Ophthalmol Vis Sci 2003; 44: 1982-1992.
98. Hafez AS, Bizzarro RL, Lesk MR. Evaluation of optic nerve head and peripapillary retinal blood flow in glaucomapatients, ocular hypertensives, and normal subjects. Am J Ophthalmol 2003; 136: 1022-1031.
99. Choritz L, Machert M, Thieme H. Correlation of endothelin-1 concentration in aqueous humor with intraocularpressure in primary open angle and pseudoexfoliation glaucoma. Invest Ophthalmol Vis Sci 2012; 53: 7336-7342.
100. Stokely ME, Brady ST, Yorio T. Effects of endothelin-1 on components of anterograde axonal transport in opticnerve. Invest Ophthalmol Vis Sci 2002; 43: 3223-3230.
101. Sasaoka M, Taniguchi T, Shimazawa M, Ishida N, Shimazaki A, Hara H. Intravitreal injection of endothelin-1 caused optic nerve damage following toocular hypoperfusion in rabbits. Exp Eye Res 2006; 83: 629-637.
102. Fitzgerald M, Payne SC, Bartlett CA, Evill L, Harvey AR, Dunlop SA. Secondary retinal ganglion cell death and the neuroprotective effects of thecalcium channel blocker lomerizine. Invest Ophthalmol Vis Sci 2009; 50: 5456-5462.
103. Karim Z, Sawada A, Kawakami H, Yamamoto T, Taniguchi T. A new calcium channel antagonist, lomerizine, alleviates secondary retinalganglion cell death after optic nerve injury in the rat. Curr Eye Res 2006; 31: 273-283.
104. Koseki N, Araie M, Tomidokoro A, Nagahara M, Hasegawa T, Tamaki Y, et al. A placebo-controlled 3-year study of a calcium blocker on visual field and ocularcirculation in glaucoma with low-normal pressure. Ophthalmology 2008; 115: 2049-2057.
105. Costa VP, Arcieri ES, Harris A. Blood pressure and glaucoma. Br J Ophthalmol 2009; 93: 1276-1282.
106. Krupin T, Liebmann JM, Greenfield DS, Ritch R, Gardiner S. A randomized trial of brimonidine versus timolol in preserving visual function:results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol 2011; 151: 671-681.
107. Neufeld AH, Das S, Vora S, Gachie E, Kawai S, Manning PT, et al. A prodrug of a selective inhibitor of inducible nitric oxide synthase isneuroprotective in the rat model of glaucoma. J Glaucoma 2002; 11: 221-225.
108. Salinas-Navarro M, Alarcon-Martinez L, Valiente-Soriano FJ, Jimenez-Lopez M, Mayor-Torroglosa S, Aviles-Trigueros M, et al. Ocular hypertension impairs optic nerve axonal transport leading to progressive retinal ganglion cell degeneration. Exp Eye Res 2010; 90: 168-183.
109. Knox DL, Eagle RC Jr, Green WR. Optic nerve hydropic axonal degeneration and blocked retrograde axoplasmic transport: histopathologic features in human high-pressure secondary glaucoma. Arch Ophthalmol 2007; 125: 347-353.
110. Pease ME, McKinnon SJ, Quigley HA, Kerrigan-Baumrind LA, Zack DJ. Obstructed axonal transport of BDNF and its receptor TrkB in experimental glaucoma. Invest Ophthalmol Vis Sci 2000; 41: 764-774.
111. Martin KR, Quigley HA, Valenta D, Kielczewski J, Pease ME. Optic nerve dynein motor protein distribution changes with intraocular pressure elevation in a rat model of glaucoma. Exp Eye Res 2006; 83: 255-262.
112. Crish SD, Sappington RM, Inman DM, Horner PJ, Calkins DJ. Distal axonopathy with structural persistence in glaucomatous neurodegeneration. Proc Natl Acad Sci U S A 2010; 107: 5196-5201.
113. Morgan JE, Datta AV, Erichsen JT, Albon J, Boulton ME. Retinal ganglion cell remodelling in experimental glaucoma. Adv Exp Med Biol 2006; 572: 397-402.
114. Liu M, Duggan J, Salt TE, Cordeiro MF. Dendritic changes in visual pathways in glaucoma and other neurodegenerative conditions. Exp Eye Res 2011; 92: 244-250.
115. Fu QL, Li X, Shi J, Xu G, Wen W, Lee DH, et al. Synaptic degeneration of retinal ganglion cells in a rat ocular hypertension glaucoma model. Cell Mol Neurobiol 2009; 29: 575-581.
116. Weber AJ, Harman CD. Structure-function relations of parasol cells in the normal and glaucomatous primate retina. Invest Ophthalmol Vis Sci 2005; 46: 3197-3207.
117. Hernandez MR. The optic nerve head in glaucoma: role of astrocytes in tissue remodeling. Prog Retin Eye Res 2000; 19: 297-321.
118. Johnson EC, Deppmeier LM, Wentzien SK, Hsu I, Morrison JC. Chronology of optic nerve head and retinal responses to elevated intraocular pressure. Invest Ophthalmol Vis Sci 2000; 41: 431-442.
119. Lam D, Jim J, To E, Rasmussen C, Kaufman PL, Matsubara J. Astrocyte and microglial activation in the lateral geniculate nucleus and visual cortex of glaucomatous and optic nerve transected primates. Mol Vis 2009; 15: 2217-2229.
120. Nguyen JV, Soto I, Kim KY, Bushong EA, Oglesby E, Valiente-Soriano FJ, et al. Myelination transition zone astrocytes are constitutively phagocytic and have synuclein dependent reactivity in glaucoma. Proc Natl Acad Sci U S A 2011; 108: 1176-1181.
121. Johnson EC, Doser TA, Cepurna WO, Dyck JA, Jia L, Guo Y, et al. Cell proliferation and interleukin-6-type cytokine signaling are implicated by gene expression responses in early optic nerve head injury in rat glaucoma. Invest Ophthalmol Vis Sci 2011; 52: 504-518.
122. Yan X, Tezel G, Wax MB, Edward DP. Matrix metalloproteinases and tumor necrosis factor alpha in glaucomatous opticnerve head. Arch Ophthalmol 2000; 118: 666-673.
123. Bringmann A, Iandiev I, Pannicke T, Wurm A, Hollborn M, Wiedemann P, et al. Cellular signaling and factors involved in Muller cell gliosis: neuroprotectiveand detrimental effects. Prog Retin Eye Res 2009; 28: 423-451.
124. Bernardos RL, Barthel LK, Meyers JR, Raymond PA. Late-stage neuronal progenitors in the retina are radial Muller glia that function as retinal stem cells. J Neurosci 2007; 27: 7028-7040.
125. Bull ND, Limb GA, Martin KR. Human Muller stem cell (MIO-M1) transplantation in a rat model of glaucoma: survival, differentiation, and integration. Invest Ophthalmol Vis Sci 2008; 49: 3449-3456.
126. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005; 308: 1314-1318.
127. Cho BP, Song DY, Sugama S, Shin DH, Shimizu Y, Kim SS, et al. Pathological dynamics of activated microglia following medial forebrain bundle transection. Glia 2006; 53: 92-102.
128. Schwartz M, Butovsky O, Bruck W, Hanisch UK. Microglial phenotype: is the commitment reversible. Trends Neurosci 2006; 29: 68-74.
129. Sappington RM, Calkins DJ. Contribution of TRPV1 to microglia-derived IL-6 and NF kappaB translocation withelevated hydrostatic pressure. Invest Ophthalmol Vis Sci 2008; 49: 3004-3017.
130. Lam TT, Kwong JM, Tso MO. Early glial responses after acute elevated intraocular pressure in rats. Invest Ophthalmol Vis Sci 2003; 44: 638-645.
131. Yuan L, Neufeld AH. Activated microglia in the human glaucomatous optic nerve head. J Neurosci Res 2001; 64: 523-532.
132. Bosco A, Inman DM, Steele MR, Wu G, Soto I, Marsh-Armstrong N, et al. Reduced retina microglial activation and improved optic nerve integrity with minocycline treatment in the DBA/2J mouse model of glaucoma. Invest Ophthalmol Vis Sci 2008; 49: 1437-1446.
133. Bull ND, Irvine KA, Franklin RJ, Martin KR. Transplanted oligodendrocyte precursor cells reduce neurodegeneration in a model of glaucoma. Invest Ophthalmol Vis Sci 2009; 50: 4244-4253.
134. Crigler L, Robey RC, Asawachaicharn A, Gaupp D, Phinney DG. Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. Exp Neurol 2006; 198: 54-64.
135. MacLaren RE, Pearson RA, MacNeil A, Douglas RH, Salt TE, Akimoto M, et al. Retinal repair by transplantation of photoreceptor precursors. Nature 2006; 444: 203-207.
136. Lamba DA, McUsic A, Hirata RK, Wang PR, Russell D, Reh TA. Generation, purification and transplantation of photoreceptors derived from human induced pluripotent stem cells. PLoS ONE 2010; 5: e8763.
137. Lamba DA, Gust J, Reh TA. Transplantation of human embryonic stem cell-derived photoreceptors restores some visual function in Crx-deficient mice. Cell Stem Cell 2009; 4: 73-79.
138. Schmitz-Valckenberg S, Guo L, Maass A, Cheung W, Vugler A, Moss SE, et al. Real-time in vivo imaging of retinal cell apoptosis after laser exposure. Invest Ophthalmol Vis Sci 2008; 49: 2773-2780.
139. Barnett EM, Zhang X, Maxwell D, Chang Q, Piwnica-Worms D. Single-cell imaging of retinal ganglion cell apoptosis with a cell-penetrating, activatable peptide probe in an in vivo glaucoma model. Proc Natl Acad Sci U S A 2009; 106: 9391-9396.